FDA Grants Orphan Drug Designation

APR Applied Pharma Research SA ("APR"), the Swiss pharma organization centered in specialty and uncommon restorative regions, declares that the US Food and Drug Administration (the "FDA") has conceded Orphan Drug Designation for its investigational tranquilize code-named APR-TD011 for treatment of Epidermolysis Bullosa ("EB"). APR-TD011 is a hypotonic corrosive oxidizing arrangement containing hypochlorous corrosi....